American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, has acquired HBT Labs, Inc. based in California. HBT Labs has a pipeline of generic and 505(b)(2) pharmaceutical products that target various treatment indications including cancer and central nervous system (CNS) disorders.

“Our acquisition of HBT Labs supports our growing product portfolio, efforts to expand into the oncology market, and dedication to better meeting the needs of providers and patients,” said Paul Diolosa, president and CEO, American Regent. “HBT’s proprietary processes and technologies to produce complex drugs will enable us to achieve our business objectives of applying innovative thinking to respond to customer needs. We look forward to working with the management team and respected staff of HBT, who are leaders in highly specialized drugs and delivery systems.”

With the acquisition, American Regent will support the existing commercialization of HBT’s authorized generic that is managed through a partner, in addition to supporting the launch of HBT’s FDA approved 505(b)(2) New Drug Application (NDA) providing for the use of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), lyophilized powder for reconstitution, 100 mg/vial.

HBT Labs will function as a wholly owned subsidiary of American Regent and will continue research and development and commercial operations in Brea, CA.